In conclusion, our study suggests progression of aortic atherosclerosis with renin inhibition in patients with established cardiovascular disease, most of whom were receiving evidence-based therapy, with >50% receiving concomitant ACEI/ARB therapy. This evidence concerns the gene REN and cardiovascular disorder.